Angewandte Chemie International Edition,
Journal Year:
2024,
Volume and Issue:
unknown
Published: Aug. 1, 2024
Abstract
Within
living
organisms,
numerous
nanomachines
are
constantly
involved
in
complex
polymerization
processes,
generating
a
diverse
array
of
biomacromolecules
for
maintaining
biological
activities.
Transporting
artificial
polymerizations
from
lab
settings
into
contexts
has
expanded
opportunities
understanding
and
managing
events,
creating
novel
cellular
compartments,
introducing
new
functionalities.
This
review
summarizes
the
recent
advancements
polymerizations,
including
those
responding
to
external
stimuli,
internal
environmental
factors,
that
polymerize
spontaneously.
More
importantly,
cutting‐edge
biomedical
application
scenarios
polymerization,
notably
safeguarding
cells,
modulating
improving
diagnostic
performance,
facilitating
therapeutic
efficacy
highlighted.
Finally,
this
outlines
key
challenges
technological
obstacles
remain
as
well
offers
insights
potential
directions
advancing
their
practical
applications
clinical
trials.
Trends in Pharmacological Sciences,
Journal Year:
2024,
Volume and Issue:
45(9), P. 839 - 857
Published: Aug. 14, 2024
Chimeric
antigen
receptor
(CAR)-engineered
T
(CAR-T)
cell
therapy
has
demonstrated
significant
success
in
treating
cancers.
The
potential
of
CAR-T
cells
is
now
being
explored
the
context
autoimmune
diseases.
Recent
clinical
trials
have
shown
sustained
and
profound
elimination
autoreactive
B
by
cells,
leading
to
promising
disease
control
with
minimal
safety
concerns.
These
encouraging
results
inspired
further
investigation
into
applications
for
a
broader
range
diseases
development
advanced
products
improved
efficacy
safety.
In
this
review,
we
discuss
mechanisms
which
target
conditions,
summarize
current
preclinical
models,
highlight
ongoing
trials,
including
design,
outcomes,
challenges.
Additionally,
limitations
future
directions
treatment
Heliyon,
Journal Year:
2024,
Volume and Issue:
10(16), P. e35836 - e35836
Published: Aug. 1, 2024
Stem
cell
transplantation
has
emerged
as
a
promising
avenue
in
regenerative
medicine,
potentially
facilitating
tissue
repair
degenerative
diseases
and
injuries.
This
review
comprehensively
examines
recent
developments
challenges
stem
transplantation.
It
explores
the
identification
isolation
of
various
types,
including
embryonic,
induced
pluripotent,
adult
cells
derived
from
multiple
sources.
Additionally,
highlights
tissue-specific
applications
these
cells,
focusing
on
bone
cartilage
regeneration,
treatment
neurological
disorders,
management
hematological
conditions.
Future
advancements
effective
resolution
current
will
be
crucial
fully
realizing
potential
medicine.
With
responsible
ethical
practices,
field
can
transform
disease
injury
treatment,
ultimately
improving
quality
life
for
countless
individuals.
Frontiers in Immunology,
Journal Year:
2024,
Volume and Issue:
15
Published: June 19, 2024
Chimeric
antigen
receptor
(CAR)
T
cell
therapy
has
effectively
complemented
the
treatment
of
advanced
relapsed
and
refractory
hematological
cancers.
The
remarkable
achievements
CD19-
BCMA-CAR
therapies
have
raised
high
expectations
within
fields
hematology
oncology.
These
groundbreaking
successes
are
propelling
a
collective
aspiration
to
extend
reach
CAR
beyond
B-lineage
malignancies.
Advanced
technologies
created
momentum
surmount
limitations
conventional
concepts.
Most
importantly,
innovations
that
enable
combinatorial
targeting
address
target
heterogeneity,
using
versatile
adapter
concepts
in
conjunction
with
recent
transformative
next-generation
design,
offer
promise
overcome
both
bottleneck
associated
manufacturing
patient-individualized
regimens.
In
this
comprehensive
review,
we
delineate
fundamental
prerequisites,
navigate
through
pivotal
challenges,
elucidate
strategic
approaches,
all
aimed
at
paving
way
for
future
establishment
multitargeted
immunotherapies
universal
technologies.
Frontiers in Cell and Developmental Biology,
Journal Year:
2023,
Volume and Issue:
11
Published: Oct. 26, 2023
Tumour-Associated
Macrophages
(TAMs)
are
one
of
the
pivotal
components
tumour
microenvironment.
Their
roles
in
cancer
immunity
complicated,
both
pro-tumour
and
anti-cancer
activities
reported,
including
not
only
angiogenesis,
extracellular
matrix
remodeling,
immunosuppression,
drug
resistance
but
also
phagocytosis
regression.
Interestingly,
TAMs
highly
dynamic
versatile
solid
tumours.
They
show
or
activities,
interplay
between
microenvironment
stem
cells
under
specific
conditions.
In
addition
to
classic
M1/M2
phenotypes,
a
number
novel
dedifferentiation
phenomena
discovered
due
advanced
single-cell
technology,
e.g.,
macrophage-myofibroblast
transition
(MMT)
macrophage-neuron
(MNT).
More
importantly,
emerging
information
demonstrated
potential
on
immunotherapy,
suggesting
by
therapeutic
efficiency
checkpoint
inhibitors
chimeric
antigen
receptor
engineered
based
macrophages.
Here,
we
summarized
latest
discoveries
from
basic
translational
research
discussed
their
clinical
relevance
for
cancers.
Bioengineering,
Journal Year:
2025,
Volume and Issue:
12(1), P. 60 - 60
Published: Jan. 13, 2025
Chimeric
Antigen
Receptor
(CAR)-engineered
T
(CAR-T)
cell
therapy
represents
a
highly
promising
modality
within
the
domain
of
cancer
treatment.
CAR-T
has
demonstrated
notable
efficacy
in
treatment
hematological
malignancies,
solid
tumors,
and
various
infectious
diseases.
However,
current
is
autologous,
which
presents
challenges
related
to
high
costs,
time-consuming
manufacturing
processes,
necessity
for
careful
patient
selection.
A
potential
resolution
this
restriction
could
be
found
by
synergizing
technology
with
induced
pluripotent
stem
(iPSC)
technology.
iPSC
inherent
capability
furnish
an
inexhaustible
reservoir
resources.
Experimental
evidence
successful
generation
human
cells
using
technology,
showcasing
yield,
purity,
robustness,
tumor-killing
efficacy.
Importantly,
enables
production
clinical-grade
cells,
significantly
reducing
costs
time,
facilitating
their
use
as
allogeneic
therapies
treat
multiple
patients
simultaneously.
In
review,
we
aim
elucidate
essential
facets
therapy,
delineate
its
utility,
enumerate
advantages
drawbacks,
offer
in-depth
evaluation
novel
pragmatic
approach
iScience,
Journal Year:
2023,
Volume and Issue:
26(10), P. 107952 - 107952
Published: Sept. 19, 2023
Ovarian
cancer
(OC)
is
highly
lethal
due
to
late
detection
and
frequent
recurrence.
Initial
treatments,
comprising
surgery
chemotherapy,
lead
disease
remission
but
are
invariably
associated
with
subsequent
relapse.
The
identification
of
novel
therapies
an
improved
understanding
the
molecular
cellular
characteristics
OC
urgently
needed.
Here,
we
conducted
a
comprehensive
analysis
primary
tumor
cells
their
microenvironment
from
16
chemonaive
10
recurrent
patient
samples.
Profiling
biomarkers
allowed
for
potential
targets
developing
immunotherapies,
while
profiling
yielded
insights
into
its
composition
property
changes
between
Notably,
identified
CD1d
as
biomarker
demonstrated
targeting
by
invariant
natural
killer
T
(iNKT)
cells.
Overall,
our
study
presents
immuno-profiling
during
progression,
guiding
development
immunotherapies
treatment,
especially
disease.
